421 related articles for article (PubMed ID: 15189460)
1. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
Babu BV; Kar SK
Trop Med Int Health; 2004 Jun; 9(6):702-9. PubMed ID: 15189460
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.
Babu BV; Rath K; Kerketta AS; Swain BK; Mishra S; Kar SK
Trans R Soc Trop Med Hyg; 2006 May; 100(5):464-9. PubMed ID: 16288792
[TBL] [Abstract][Full Text] [Related]
3. Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance.
Babu BV; Mishra S
Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1207-13. PubMed ID: 18632125
[TBL] [Abstract][Full Text] [Related]
4. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.
Krentel A; Fischer P; Manoempil P; Supali T; Servais G; Rückert P
Trop Med Int Health; 2006 Nov; 11(11):1731-40. PubMed ID: 17054754
[TBL] [Abstract][Full Text] [Related]
5. Knowledge and perceptions about lymphatic filariasis: a study during the programme to eliminate lymphatic filariasis in an urban community of Orissa, India.
Rath K; Nath N; Shaloumy M; Swain BK; Suchismita M; Babu BV
Trop Biomed; 2006 Dec; 23(2):156-62. PubMed ID: 17322817
[TBL] [Abstract][Full Text] [Related]
6. Community-based study to assess the efficacy of DEC plus ALB against DEC alone on bancroftian filarial infection in endemic areas in Tamil Nadu, south India.
Rajendran R; Sunish IP; Mani TR; Munirathinam A; Arunachalam N; Satyanarayana K; Dash AP
Trop Med Int Health; 2006 Jun; 11(6):851-61. PubMed ID: 16772007
[TBL] [Abstract][Full Text] [Related]
7. Mass drug administration against lymphatic filariasis: experiences from Kozhikode district of Kerala State.
Regu K; Showkath Ali MK; Rajendran R; Koya SM; Ganesh B; Dhariwal AC; Lal S
J Commun Dis; 2006 Dec; 38(4):333-8. PubMed ID: 17913209
[TBL] [Abstract][Full Text] [Related]
8. Changes in Wuchereria bancrofti infection in a highly endemic community following 10 rounds of mass administration of diethylcarbamazine.
Ramaiah KD; Vanamail P; Das PK
Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):250-5. PubMed ID: 16890256
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance through consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka.
Gunawardena S; Sri Ranganathan S; Fernandopulle R
Trop Med Int Health; 2008 Sep; 13(9):1153-8. PubMed ID: 18631319
[TBL] [Abstract][Full Text] [Related]
10. Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities.
Burkot TR; Taleo G; Toeaso V; Ichimori K
Ann Trop Med Parasitol; 2002 Dec; 96 Suppl 2():S61-9. PubMed ID: 12625919
[TBL] [Abstract][Full Text] [Related]
11. Study on the factors affecting the MDA programme in Kerala state.
Showkath Ali MK; Rajendran R; Regu K; Mohanan MK; Dhariwal AC; Lal S
J Commun Dis; 2007 Mar; 39(1):51-6. PubMed ID: 18338717
[TBL] [Abstract][Full Text] [Related]
12. Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008.
Cantey PT; Rao G; Rout J; Fox LM
Trop Med Int Health; 2010 Feb; 15(2):224-31. PubMed ID: 20002615
[TBL] [Abstract][Full Text] [Related]
13. Knowledge on lymphatic filariasis and mass drug administration (MDA) programme in filaria endemic districts of Andhra Pradesh, India.
Mukhopadhyay AK; Patnaik SK; Satya Babu P; Rao KN
J Vector Borne Dis; 2008 Mar; 45(1):73-5. PubMed ID: 18399322
[No Abstract] [Full Text] [Related]
14. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007).
Hooper PJ; Bradley MH; Biswas G; Ottesen EA
Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394
[TBL] [Abstract][Full Text] [Related]
15. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India.
Nandha B; Krishnamoorthy K; Jambulingam P
Health Educ Res; 2013 Aug; 28(4):591-8. PubMed ID: 23503571
[TBL] [Abstract][Full Text] [Related]
16. Coverage survey for assessing mass drug administration against lymphatic filariasis in Gulbarga district, Karnataka, India.
Ranganath BG
J Vector Borne Dis; 2010 Mar; 47(1):61-4. PubMed ID: 20231778
[No Abstract] [Full Text] [Related]
17. A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.
Ramaiah KD; Vijay Kumar KN; Hosein E; Krishnamoorthy P; Augustin DJ; Snehalatha KS; Nanda B; Das PK
Ann Trop Med Parasitol; 2006 Jun; 100(4):345-61. PubMed ID: 16762115
[TBL] [Abstract][Full Text] [Related]
18. Preventing confusion about side effects in a campaign to eliminate lymphatic filariasis.
Ramaiah KD; Ravi R; Das PK
Trends Parasitol; 2005 Jul; 21(7):307-8. PubMed ID: 15923141
[No Abstract] [Full Text] [Related]
19. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study.
Stolk WA; Swaminathan S; van Oortmarssen GJ; Das PK; Habbema JD
J Infect Dis; 2003 Nov; 188(9):1371-81. PubMed ID: 14593597
[TBL] [Abstract][Full Text] [Related]
20. Use of an inclusive-partnership strategy in urban areas of Orissa, India, to increase compliance in a mass drug administration for the control of lymphatic filariasis.
Babu BV; Behera DK; Kerketta AS; Mishra S; Rath K; Swain BK; Mishra S; Kar SK
Ann Trop Med Parasitol; 2006 Oct; 100(7):621-30. PubMed ID: 16989688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
